ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "dermatomyositis and patient outcomes"

  • Abstract Number: 2284 • 2018 ACR/ARHP Annual Meeting

    Safety and Efficacy of Lenabasum in Refractory Skin-Predominant Dermatomyositis Subjects Treated on an Open-Label Extension of Trial JBT101-DM-001

    Victoria P. Werth1,2, David Pearson1,2, Joyce Okawa1,2, Rui Feng3, Josef Concha1,2, Basil Patel1,2, Emily Hejazi1,2, Caitlin Cornwall4, Scott Constantine4 and Barbara White4, 1University of Pennsylvania, Philadelphia, PA, 2Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, 3University of Pennsylvania, Philadelphia', PA, 4Corbus Pharmaceuticals, Inc., Norwood, MA

    Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses. Lenabasum had acceptable safety and tolerability…
  • Abstract Number: 2977 • 2018 ACR/ARHP Annual Meeting

    Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Reduces T-Cell Population and Downregulates Type 1 and 2 Interferon Activities in Lesional Dermatomyositis Skin

    Nithin Reddy1,2, Majid Zeidi1,2, Barbara White3 and Victoria P. Werth1,2, 1University of Pennsylvania, Philadelphia, PA, 2Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, 3Corbus Pharmaceuticals, Inc., Norwood, MA

    Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 (CB2) agonist that activates resolution of innate immune responses. CB2 is a G-protein coupled…
  • Abstract Number: 2156 • 2017 ACR/ARHP Annual Meeting

    Comparison of Patients with Dermatomyositis in a Specialty Clinic Versus Clinical Trial with Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist

    Victoria P Werth1, Emily Hejazi2, Sandra M. Pena3, Jessica S. Haber4, Joyce Okawa3, Rui Feng5, Kirubel Gabre2, Josef Concha2, Scott Constantine6 and Barbara White6, 1University of Pennsylvania and the VA Medical Center, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 4Department of Dermatology, University of Pennsylvania, Philadelphia, PA, 5Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA, 6Corbus Pharmaceuticals, Inc., Norwood, MA

    Background/Purpose: There are limited treatment options and no published double-blind randomized placebo-controlled trials for the treatment of skin manifestations of dermatomyositis (DM).  There is no…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies